` SPRC (Scisparc Ltd) vs S&P 500 Comparison - Alpha Spread

SPRC
vs
S&P 500

Over the past 12 months, SPRC has underperformed S&P 500, delivering a return of -93% compared to the S&P 500's +12% growth.

Stocks Performance
SPRC vs S&P 500

Loading
SPRC
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
SPRC vs S&P 500

Loading
SPRC
S&P 500
Difference
www.alphaspread.com

Performance By Year
SPRC vs S&P 500

Loading
SPRC
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Scisparc Ltd vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Scisparc Ltd
Glance View

Market Cap
2.2m USD
Industry
Biotechnology

Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The firm is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.

SPRC Intrinsic Value
2.149 USD
Undervaluation 69%
Intrinsic Value
Price
Back to Top